肝泡型包虫病的手术治疗:附43例病例分析

目的 探讨肝泡型包虫病手术治疗的方式和疗效.方法 对我院2000年至2008年收治的43例肝泡型包虫病患者分成两组回顾性分析.根治性手术组19例、姑息性手术组24例.结果 姑息性手术组围手术期病死1例,2例术后出现远处转移,2例术后出现肝内播散,4例因术后再次出现黄疸、3例因术后反复发作胆管炎而入院治疗.根治性手术组3例术后出现胆瘘,1例出现胆管炎,3例出现消瘦.术后30例获得随访(≤3年至≤8年).随访期间,姑息性手术组有10例患者病死,长期生存率为28.5%(4/14);根治性手术组中有1例患者因贲门癌病死,长期生存率为93.7%(15/16).结论 根治性手术是治疗肝泡型包虫病的首选方法.可使患者获得临床治愈并长期存活.而姑息性手术多用于解决梗阻性黄疸或并发症,以便为进一步治疗争取时间.

Abstract：

Objective To study the operative techniques and the surgical results of hepatic alveolar echinococcosis. Methods Forty three patients with hepatic alveolar echinococcosis treated in our Hospital from 2000 to 2008 were studied retrospectively. They were divided into two groups: radical resection group (19 cases) and palliative resection group (24 cases). Results There were 1 surgeryrelated death, 2 patients with remote metastases, 2 patients with intrahepatic dissemination, 4 patients with recurrent jaundice and 3 patients with cholangitis in the palliative resection group. There were 3 patients with biliary fistula, 1 patient with cholangitis and 3 patients with emaciation in the radical resection group. Among the 30 patients followed-up for ≤3-≤8 years, 10 patients died in the palliative resection group and the long-term survival rate was 28.5% (4/14). One patient died from gastric cancer in the cardiac in the radical resection group and the long survival rate was 93. 7%(15/16). Conclusions The first choice of treatment for hepatic alveolar echinococcosis is radical resection. Patients could be cured by radical resection. Palliative surgery is an option for patients not manageable otherwise.     

肝移植治疗肝内胆管结石和肝包虫病

目的探讨肝移植治疗合并胆汁性肝硬化的广泛肝内胆管结石和不能手术治疗的肝包虫病的效果。方法对2例广泛肝内胆管结石伴胆汁性肝硬化和4例不能手术切除的肝包虫病(泡球蚴病)患者施行原位肝移植，术后定期随访，评价疗效。结果2例胆管结石患者已存活2年多：4例肝包虫病患者，除1例术后3个月死于心力衰竭外，其余3例已分别存活9个月、15个月及2年；存活患者均恢复了正常生活和工作。结论肝移植可作为治疗广泛肝内胆管结石和不能手术治疗的肝包虫病的有效手段。     

142例肝门胆管癌的外科治疗及预后分析

目的比较不同治疗方法对肝门胆管癌预后的影响。方法回顾性研究我院1983～2003年收治的142例肝门胆管癌的临床资料。结果142例中手术切除103例，根治性切除(R0)组50例、非根治性切除(R1，R2)组53例。引流39例：切除者中联合不同范围肝切除者36例、未切肝者67例；引流组中开腹引流15例、非开腹组24例。(1)根治性切除组1、2、3和5年生存率分别为90．61％、59．55％、40．23％和24．76％，非根治性切除组1、2、3和5年生存率分别为49．60％、8．77％、4．38％和4．38％；(2)开腹及未开腹引流组1年生存率分别为26．00％和37．31％，无2年生存者。(3)切肝组1、2、3和5年生存率分别为87．43％、51．04％、36．46％和25．52％，非切肝组1、2、3和5年生存率分别为55．82％、22．41％、12．80％和6．40％。结论术前正确评价可切除性、术中选择适宜的手术方式、合理应用肝切除术是提高疗效的关键问题。在开腹手术中，根治性切除(R0)的效果最佳，非根治性切除(R1，R2)的效果要优于单纯旁路手术；对于非手术处理，支架内引流术的效果优于PTCD。     

肝细胞肝癌合并胆总管癌栓的外科治疗

目的 通过对肝细胞肝癌合并胆总管癌栓手术病例临床资料的回顾性分析,探讨不同手术方式的疗效以及对远期预后的影响.方法 2008年1月-2012年12月,北京协和医院肝脏外科收治肝细胞肝癌合并胆总管癌栓行手术病例共9例,5例病例行根治性半肝切除术,3例行肝部分切除术,1例行术中射频,全部病例均行胆总管探查取栓术;术后通过数字减影血管成像技术进行随诊;全部病例术后随访时间均超过12个月.结果 全部手术病例术后黄疸指数均明显下降,根治性手术病例术后无瘤生存时间、生存时间均略优于姑息手术病例,术后再次胆道梗阻发病率也低于姑息手术病例.结论 肝细胞肝癌合并胆总管癌栓病例通过适当的手术方式可以达到切除肿瘤、解除胆道梗阻的目的,根治性半肝切除术的疗效优于肝部分切除术.     

Timing of Two-stage Liver Resection during Chemotherapy for Otherwise Unresectable Colorectal Metastases

Background

Tumor downsizing by effective chemotherapy while increasing remnant liver volume by two-stage hepatectomy can expand eligibility for resection of otherwise unresectable liver metastases. However, optimal timing of two-stage hepatectomy with respect to chemotherapy is undetermined.

Methods

We retrospectively analyzed the effect of timing of two-stage hepatectomy and chemotherapy using data from 95 patients whose colorectal liver metastases initially were considered unresectable.

Results

In 21 of 22 (95?%) patients whose first liver resection preceded chemotherapy (Hx-CTx group) and in 39 of 73 (53?%) patients whose chemotherapy preceded surgery (CTx-Hx group), macroscopic complete resection ultimately was achieved (P?P?P?=?0.12 and P?=?0.24, respectively), although poor response to chemotherapy was more frequent in the Hx-CTx group.

Conclusions

Optimal timing of hepatectomy and chemotherapy is difficult to specify, but performing the initial resection in a two-stage hepatectomy before chemotherapy may increase likelihood of macroscopic complete resection, even in patients with a poor response to chemotherapy or with limited courses of chemotherapy.     

Intrahepatic cholangio-jejunostomy in patients with unresectable carcinoma of the biliary tract and pancreas

We have experienced 59 jaundiced patients with unresectable carcinoma of the biliary tract or pancreas in our institute for 7 years and 6 months. A side-to-side anastomosis between a bile duct in the segment III of the liver and jejunum by Roux-en Y manner was preferred as a palliative internal drainage operation in 13 cases out of them. The operative procedure was described in details. There was no operative death. The postoperative complications occurred in 4 cases, 2 at early and 2 at late phase, respectively. However, they were all recovered within a short period. Mean survival time after the surgery was 8.9 months. The longest survivor died of primary lesion at 25.5 months. In 6 out of 7 patients who survived more than 6 months, performance status was improved after surgery. Indication of this surgery was discussed based on our experiences. It should be emphasized that good palliation may be expected by this procedure for unresectable carcinoma of the biliary tract or pancreas.     

肝内胆管结石外科手术方法探讨

目的: 探讨肝内胆管结石并狭窄的手术治疗方法及其效果。方法: 总结8年间住院的165例肝内胆管结石并胆管狭窄患者的外科手术治疗情况。其中A组85例行肝叶(或肝段)切除的各种术式，同时行胆管空肠吻合40例，肝断面扩张胆管、肝门胆管与空肠双口吻合10例，T管和U管引流分别为21例和14例；B组80例行非肝叶(或肝段)切除术的各种术式，其中胆总管切开取石+T管引流23例，胆总管切开取石+U形管引流15例，胆肠吻合+胆总管取石42例。肝门部肝胆管狭窄整形46例。结果: A组无手术死亡；随访2～7年，术后残留结石4例，残石率4.71%；症状复发3例，复发率3.53%，无再手术者。B组无手术死亡；B组随访2～7年，术后残留结石12例，残石率15.00%。10例术后常有上腹隐痛或发热，症状复发率12.5%。术后经胆道镜取石5例，其余6例中有3例再次行肝叶切除治愈。结论: 肝段(叶)切除联合其他手术是治疗肝内胆管结石较为理想而有效的手术方式。     

肝泡型包虫病根治性切除163例回顾性分析

目的:探讨肝泡型包虫病根治性切除的治疗效果。方法:回顾性分析2013年1月—至2015年6月163例行根治性切除肝泡型包虫病患者的临床资料。结果:根治性手术平均时间(3.1±1.2)h,术中出血量(763±498)m L。术后携带腹腔引流管中位时间6 d,11例携带T管,术后1个月拔除。术后平均肛门排气时间(2.1±0.8)d、经口进食时间(2.7±1.1)d、住院时间(7.9±3.4)d。8例出现术后并发症,其中5例术后胆瘘,1例术区感染,2例术后腹水。术后电话或门诊随访1~6个月无死亡及包虫复发情况。结论:根治性切除是当前肝泡型包虫病患者的首选治疗方案。术前充分评估手术可行性,术中充分掌握肝脏血流控制、肝脏外科解剖、门静脉重建、胆管重建等技术,通过根治性手术切除可明显改善泡型包虫病患者的生存质量,延长患者的生存时间。     

肝外胆管癌的外科治疗与预后分析(附107例报告)

目的探讨肝外胆管癌（EHCC）的临床特征、治疗方法对远期生存率的影响，研究EHCC切除术后的预后因素。方法对1995年1月至2003年12月收治的107例EHCC的临床特点、诊断、手术方式和随访结果进行回顾分析。选择对EHCC切除术后预后可能产生影响的临床因素，通过Cox比例风险模型进行多因素的预后分析。结果107例手术治疗的EHCC，根治性切除47例（其中单纯骨骼化切除7例，联合各类肝叶切除12例，联合门静脉切除重建3例，联合胰十二指肠切除25例），姑息性切除12例，内或外引流术45例，探查性手术3例。EHCC总体生存率1，3，5年生存率分别为58．2％、30．0％和13．1％。其中根治性切除1，3，5年生存率分别为72．4％、44．7％和22．7％；姑息性切除1，2，3年生存率分别为54．5％、27．3％和9．1％，无5年存活者。引流组1，2，3年生存率分别为32．1％、17．2％和8．6％，无4年存活者。根治性切除组、姑息性切除组、内或外引流组及非手术组生存率相比较，差异有统计学意义（log-rank test，x^2=15．67，P〈0．001）。肿瘤的组织学类型、TNM分期、淋巴结转移、肝脏浸润、胰腺浸润、切缘癌残留、手术切除方式7个因素对预后的影响差异有统计学意义（P〈0．05）。结论根治性切除是提高EHCC远期生存率及改善生活质量的关键，骨骼化切除联合肝叶切除和（或）胰十二指肠切除是提高远期疗效的重点。淋巴结转移、切缘癌残留是EHCC切除影响预后的独立因素。     

Hepatic alveolar echinococcosis: clinical report from an endemic region.

OBJECTIVE: To review the clinical management of alveolar echinococcosis. DESIGN: A retrospective analysis. SETTING: A university-affiliated hospital in Turkey. PATIENTS: Forty patients treated for alveolar echinococcosis between 1987 and 2000. INTERVENTIONS: Curative resection followed by chemotherapy, or medical palliation with chemotherapy only. Palliative procedures such as bilioenteric or external drainage were done for cholestatic jaundice and liver abscess. OUTCOME MEASURES: Results of medical and surgical treatment. RESULTS: Seventeen patients had a resectable tumour and all underwent curative resection. Of the other 23 patients with nonresectable tumour, 11 underwent palliative surgical procedures such as bilioenteric or external drainage for cholestatic jaundice or liver abscess. All patients received long-term albendazole therapy. Four patients with nonresectable tumour died because of chronic liver failure. In a 6.5-year follow-up, there was no recurrence in patients who underwent curative resection. The efficacy of chemotherapy is limited in nonresectable disease. CONCLUSIONS: To increase the rate of early detection and curative resection, screening programs are essential. Research on new chemotherapeutic approaches should be made to improve survival in patients with nonresectable disease.     

El trasplante hepático aumenta la resecabilidad R0 y la supervivencia de los pacientes con tumor de Klatskin irresecable no diseminado

IntroductionThere are no established indications for Liver transplant (LT) in patients with a Klatskin tumour (KT) due to the differences in the published results.ObjectiveTo report on our patients who have non-disseminated unresectable KT and who were given a LT, and to compare results with those of patients who have had tumour resection and those who have not.Patients and methodWe have treated 75 patients diagnosed with KT. The mean age was 62±11 years (range: 38–88 years) and 50 were males (66%). Twenty patients were inoperable. Of the 55 patients who underwent surgery: tumour resection (TR) was performed in 29 cases; there was no tumour dissemination in 11 unresectable cases and therefore these patients were added to the LT waiting list and the remaining 15 unresectable cases had tumour dissemination and remained on palliative treatment.ResultsIn the LT group there was no postoperative mortality (during the first month) and the survival rate was 95%, 59% and 36% with a disease-free survival of 75%, 40% and 20%; whereas the patients given RT had a survival rate of 80%, 52% and 38% at 1, 3 and 5 years, with a disease-free survival of 65%, 35% and 19%, without any differences compared to the LT group. Patients with unresectable tumour left on palliative therapy had a lower survival than the unresectable who underwent LT (p<0.001).ConclusionsIn patients with non-disseminated unresectable KT, LT has a similar survival to that obtained in cases with resectable R0 liver resection. LT improves the survival rate achieved using palliative treatment in patients with non-disseminated unresectable KT.     

晚期胆管癌姑息性切除、光动力治疗及支架引流疗效的Meta分析

目的评价晚期胆管癌患者姑息性R1、R2切除与支架引流治疗的疗效及光动力治疗与支架引流的疗效。 方法计算机检索PUBMED、中国生物医学文献数据库(CBMdisc)、万方数据库、中国学术期刊全文数据库(CNKI),查找1980年1月至2013年12月发表的有关对比分析胆管癌姑息性(R1、R2)切除与支架引流治疗及光动力治疗与支架引流治疗效果的随机对照试验文献。按照纳入与排除标准选择文献、提取资料、评价质量后,采用RevMan 5.2软件进行Meta分析。 结果共有9篇研究585例患者纳入姑息性R1、R2切除和支架引流分析,其中姑息性切除组208例,支架引流组377例。共有4篇研究纳入光动力治疗和支架引流分析,包括252例患者,其中光动力治疗组132例,引流治疗组120例。分析显示:总体并发症发生率、死亡率、1年生存率指标中,姑息性R1、R2切除组与引流治疗组相比1年生存人数较多,差异有统计学意义[(OR 0.79,95%CI 0.42~1.50,P=0.48)、(RD-0.00,95%CI-0.04~0.04,P=0.94)、(OR 2.87,95%CI 1.82~4.54,P<0.05)],胆瘘发生率、胆管炎或胆道梗阻发生率差异无统计学意义[(OR 1.74,95%CI 0.73~4.17,P=0.21)、(OR 0.50, 95%CI 0.22~1.12,P=0.09)]。光动力治疗组和支架引流的疗效对比中光动力治疗术后生存时间较支架引流明显延长。 结论晚期胆管癌患者R1、R2切除及光动力疗效均好于单纯支架引流,但光动力治疗与手术相比是一种安全、恢复快、创伤小的治疗方式。     

Tumeur de Klatskin. Étude de 15 cas réséqués

Study aimKlatskin tumors are rare. Prognosis is still poor, and long term survival can be expected only after surgery, which is the treatment of choice. The aim of this study is to report the results of 15 resected cases and, by analysis of the literature, to emphasize the progress of the surgical treatment in hilar cholangiocarcinoma.Patients and methodsBetween 1990 and 1998, 27 patients affected by Klatskin tumor were observed. Eight women and seven men underwent surgical resection. The mean age was 59 years. Thirteen patients (48%) had curative resection (7 hilar resection (HR), 5 HR combined with partial hepatectomy (PH) and 1 HR+PH with portal vein resection). Two patients had palliative resection and surgical drainage.ResultsOne in-hospital death occurred right after hepatectomy with portal vein resection (6.6%). Postoperative morbidity was 40%. Patients were regularly followed. Ten patients died and 5 were alive at the time of this study. The 1, 2 and 3-year survival after a curative resection was 84%, 54% and 34%. The median survival was 28.5 months. Lymph node involvement did not show a statistically significant difference on median survival between the positive group and the negative group (26.2 vs 29.8 months) because of the small number of patients. Survival after hilar resection at 1, 2, 3, and 5 years was 100%, 57.1%, 28.6% and 0%. Four out of the 6 patients who underwent hilar resection combined with partial hepatectomy were still alive 1, 23, 29, 38 months after resection. Hepatectomy increased mortality (16% vs 0%). Palliative biliary resection and surgical drainage were successfully performed in 2 patients.ConclusionAggressive surgical treatment of Klatskin tumor can improve the survival of patients. Careful preoperative management has to be carried out by a multidisciplinary approach including surgeons, hepatologists, radiologists and pathologists. Hepatic resection including the caudate lobe is often performed in order to obtain microscopic tumor-free margins and curative resection (R0). Biliary drainage and treatment of cholangitis is mandatory before surgery in order to improve the surgical outcome. Surgical treatment is characterized by high technical difficulties, and better results can be achieved by hepatobiliary surgical teams.     

Hepatocellular carcinoma presenting with obstructive jaundice

BACKGROUND: Jaundice occurs in 5-44% of patients with hepatocellular carcinoma (HCC). It is an important clinical presentation as the different aetiological causes of jaundice in HCC determine the therapeutic approach and the prognosis. This article aims to review the classification, management and prognosis of patients with jaundice associated with HCC. METHODS: A Medline search was undertaken to identify articles using the key words 'hepatocellular carcinoma', 'jaundice' and 'tumour thrombus'. Additional articles were identified by a manual search of the references from the key articles. RESULTS: Patients with jaundice due to hepatic parenchymal insufficiency (hepatocellular type) have a very dismal prognosis. For patients with biliary obstruction due to HCC (icteric type), the reported 1-, 3- and 5-year survival rates after curative resection were 57.1-100%, 20-47% and 6.7-45%, respectively. The mean survival after palliative biliary drainage alone was less than 6 months but when biliary drainage was combined with other palliative treatment, the mean survival could be up to 1 year. CONCLUSIONS: It is important to differentiate the hepatocellular type from the icteric type of HCC. For patients with the icteric type of HCC, curative liver resection can achieve a survival comparable to that in patients without jaundice. For patients with unresectable icteric type of HCC, treatment can provide improvement in patient's quality of life and survival.     

Die chirurgische Therapie der alveolären Echinokokkose und deren Langzeitergebnisse

INTRODUCTION: The incidence of alveolar echinococcosis (AE) is low, and studies and progress reports with regard to surgical procedures are rare. METHODS: Retrospective analysis of surgical therapy of AE and its long-term results between 1983 and 2000 by evaluating medical records and questionnaires. SETTING: German university hospital within the endemic area. RESULTS: Twenty-five surgical procedures were performed in 19 patients with AE (12x partial resection of the liver, 3 of them with additional extrahepatic resection; 3x just extrahepatic resection, 4x bilidigestive anastomosis, 5x exploratory laparotomy, 1x bypass procedure). Fifteen patients were operated on the first time with that diagnosis, four due to a relapse. Seven surgical procedures were estimated to be curative, whereas 18 were palliative, because the parasitic mass could not be resected in toto. One patient died from persistent systemic sepsis as a consequence of microbial superinvasion of a splenic parasitic mass. Morbidity was 28%. All patients had additional medical treatment and periodic follow-up. Three of seven patients estimated for curative surgery developed a relapse. One of the patients discharged following palliative surgery died 13 years after diagnosis with liver insufficiency. Advances in conservative and interventional treatments have greatly improved the prognosis of the disease. CONCLUSION: Curative surgery for AE is feasible only in a minority of patients, because frequently the disease has already spread widely when diagnosed. The minimum distance between the lesion and the cut surface should be 2 cm. Taking the advances in conservative treatment into consideration, the benefit of palliative surgery is uncertain and today there is no evidence for prolonged survival by palliative surgical procedures. Palliative surgery should therefore be reserved for cases with complications that could not be managed by conservative and interventional treatment.     

Role for extending hepatic resection using an aggressive approach to liver surgery

BACKGROUND: The definition of what is unresectable in liver surgery is controversial. Problems that many believe render patients unresectable can currently be resected using advanced techniques of liver surgery. This study assesses liver resection in patients who were unresectable with standard liver resection but were potentially resectable using an aggressive approach to liver surgery. STUDY DESIGN: From 1997 to 2007, 830 adult patients undergoing hepatectomy were reviewed. Patients were categorized as having unresectable disease by standard resection if the disease could not be resected without resection of the IVC, hepatic vasculature, or because of tumor extent. RESULTS: One hundred sixteen patients were initially believed to have unresectable disease but went on to laparotomy. Eighteen patients were unresectable at operation, although 98 patients were resected. Seventy-eight trisectionectomies; 18 lobectomies; 1 mesohepatectomy; and 1 segment 5, 6 resection, combined with pancreaticoduodenectomy, nephrectomy, and colectomy, were performed. Fourteen patients also had pancreatic resections. Vascular reconstructions were performed on the IVC (n = 35), hepatic veins (n = 21), portal vein (n = 34), and hepatic artery (n = 5). Hypothermic perfusion of the liver was used in 12 patients (4 ex vivo, 8 in situ cold perfusion). Patients undergoing resection had 6% mortality with a morbidity of 35%. Median survival was 37 months (95% CI, 34-42 months). Five-year actuarial survival was 32%. CONCLUSIONS: Patients with liver tumors considered "unresectable" by standard liver resection should be considered for resection with an aggressive approach to liver surgery. Five-year survival of approximately one-third of patients can be expected.     

Combined portal vein and liver resection for carcinoma of the biliary tract

Twenty-nine patients with advanced carcinoma of the bile duct or gallbladder underwent combined portal vein and liver resection. Segmental excision of the portal vein was performed in 16 cases and wedge resection of the vessel wall in 13. The operative mortality rate was 17 per cent. The median survival for the 24 patients who left hospital was 19.8 months. Actuarial survival rates at 1, 3 and 5 years for all 29 patients were 48 per cent, 29 per cent, and 6 per cent respectively, whereas the median survival for 46 patients with unresectable carcinoma was 3 months and the 1 and 3-year actuarial survival rates were 13 per cent and zero respectively. This difference in survival times between patients undergoing hepatectomy with portal vein resection and those with unresectable carcinoma were statistically significant (P less than 0.01). Combined portal vein and liver resection is recommended as a reasonable surgical approach in selected patients with advanced carcinoma of the biliary tract.     

Changing Strategies in Diagnosis and Management of Hilar Cholangiocarcinoma

Hilar cholangiocarcinoma is one of the most difficult tumors to stage and treat. This study aims to evaluate (1) the best diagnostic imaging, (2) the usefulness of preoperative biliary drainage, (3) the resectability rate, and (4) the results of palliative treatments and surgical resection. Seventy-six patients with hilar cholangiocarcinoma with a mean age of 64 ± 11 years were treated at our institution from 1989 to 1999. Patients were studied preoperatively using ultrasound, computed tomography (CT), and percutaneous cholangiography or magnetic resonance cholangiography. Forty-eight patients (63%) underwent palliative treatment. Twenty-eight patients underwent surgical curative therapy; 20 resections and 8 orthotopic liver transplantations (OLTs). Percutaneous transhepatic cholangiography was performed in 18 of 28 patients (64%), and magnetic resonance cholangiography in 5 patients; both methods were equally effective in establishing tumoral invasion of the biliary ducts. Five patients did not undergo either diagnostic modality. Excluding the patients who underwent OLT, no significant differences were found in surgical mortality (1 v 2 patients) or postoperative morbidity (100% v 66%) for patients with and without preoperative biliary drainage. The postoperative mortality rate was 11% (3 of 28 patients). The overall resectability rate was 37%. Mean survival in the surgical and palliative groups was 35 and 6 months, respectively (P < .0001). Patients who underwent OLT had a better 5-year survival rate than those treated by tumor resection (36% v 21%; P = .02). Combined chemotherapy and radiotherapy apparently did not provide a significant survival benefit. Helical CT and magnetic resonance cholangiography are useful techniques to delineate tumor extent and rule out vascular invasion and lymph node or liver metastases. No clear conclusions regarding preoperative drainage can be drawn from this study. A high resectability rate (37%) is feasible with major hepatectomy. (Liver Transpl 2000;6:786-794.)     

Resection, including transplantation, for hepatoblastoma and hepatocellular carcinoma: impact on survival.

Long-term survival in children with primary hepatic malignancies can not be expected without complete tumor resection. In the last ten years we have treated 21 children with hepatocellular carcinoma (HCC) and 21 children with hepatoblastoma (HEP), with tumor extirpation our surgical goal. Operative treatment included partial hepatectomy ([PH] 20), either primary (10) or delayed (following chemotherapy) (10), total hepatectomy and orthotopic liver transplantation ([OLT] 13), or upper abdominal exenteration and multiple organ transplantation (2). Two patients had both PH and subsequent total hepatectomy and OLT. Overall survival was 48% (20/42), with 9 patients dying of progressive disease prior to removal of their tumor. HEP patient survival was 67% (14/21), including 2 of 6 who underwent primary PH, 7 of 8 who had delayed PH, and 5 of 6 who underwent OLT. Survival for the children with HCC was 29% (6/21), including 1 of 4 after primary PH, 1 of 2 following delayed PH, 3 of 7 following OLT, and 1 of 2 after exenteration and multiple organ transplantation. Preoperative chemotherapy facilitated removal of 10 initially unresectable tumors (8 HEP, 2 HCC) at a second-look procedure. Total hepatectomy and OLT markedly improved survival in patients with disease unresectable by standard methods. Partial hepatectomy, either primary or delayed, should be attempted in all children with hepatic malignancies. Total hepatectomy and OLT appears to be a viable adjunct in the treatment of childhood malignancies, and should be used for otherwise unresectable tumors as part of a carefully planned protocol.     

Surgical management of recurrence after resection of colorectal liver metastases

The optimal treatment for recurrent lesions after hepatectomy for colorectal liver metastases is controversial. We report the outcome of aggressive surgery for recurrent disease after the initial hepatectomy and the influence on quality of life of such treatment. Forty-five (70%) of the 64 surviving patients developed recurrence after the initial hepatectomy for liver metastases. The determinants of hepatic recurrence were the distribution and the number of liver metastases. Twenty-eight (62%) of patients with recurrence underwent resection. A second hepatectomy was performed in 20 patients, and a third hepatectomy was done in 5 patients. Ten patients with pulmonary metastasis underwent partial lung resection on 14 occasions, while resection of brain metastases was performed in 3 patients on 5 occasions. There were no operative deaths after resection of recurrent disease. The morbidity rate was 28% after repeat hepatectomy, 21% after pulmonary resection, and 0% after resection of brain metastasis. The Karnofsky performance status (PS) after the last surgery was not significantly different from that after the initial hepatectomy. The 3- and 5-year survival rates after the second hepatectomy were 54% and 14%, respectively. The 3-and 5-year survival rates of the patients undergoing resection of extrahepatic recurrence were both 17%. The survival rate after resection of recurrent disease (n=28) was significantly better than that of patients (n=17) with unresectable recurrence (P < 0.05). For the 66 patients with colorectal liver metastases, the 5-year survival rate after initial hepatectomy was 50%. The distribution and the number of liver metastases and the presence of extrahepatic disease, as single factors, significantly affected prognosis after the initial hepatectomy. Multivariate analysis revealed that only the presence of extrahepatic metastasis and a disease-free interval of less than 6 months were independent predictors of survival after the initial and second hepatectomy, respectively. It is concluded that aggressive surgery is an effective strategy for selected patients with recurrence after initial hepatectomy. Careful selection of candidates for repeat surgery will yield increased clinical benefit, including long-term survival.